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Late-onset depressive symptoms increase
the risk of dementia in small vessel disease
ABSTRACT
Objective: We prospectively investigated the role of depressive symptoms (DS) on all-cause
dementia in a population with small vessel disease (SVD), considering onset age of DS and cog-
nitive performance.
Methods: The RUN DMC study (Radboud University Nijmegen Diffusion Tensor and Magnetic
Resonance Cohort) is a prospective cohort study among 503 older adults with SVD on MRI with-
out dementia at baseline (2006), with a follow-up of 5 years (2012). Kaplan-Meier curves strat-
ified for DS and dementia risk were compared using log-rank test. We calculated hazard ratios
using Cox regression analyses.
Results: Follow-up was available for 496 participants (mean baseline age 65.6 years [SD 8.8];
mean follow-up time 5.2 years). All-cause dementia developed in 41 participants. The 5.5-year
dementia risk was higher in those with DS (hazard ratio 2.7, 95% confidence interval 1.4–
5.2), independent of confounders. This was driven by those with late-onset DS. Five-year cumu-
lative risk difference for dementia was higher in participants with depressive symptoms who had
high baseline cognitive performance (no DS 0.0% vs DS 6.9%, log-rank p , 0.001) compared
with those who had low cognitive performance at baseline.
Conclusions: Late-onset DS increases dementia risk, independent of SVD. Especially in those
with relatively high cognitive performance, DS indicate a higher risk. In contrast to current prac-
tice, clinicians should monitor those with DS who also show relatively good cognitive test scores.
Neurology® 2016;87:1102–1109
GLOSSARY
CES-D 5 Center for Epidemiologic Studies Depression Scale; CI 5 confidence interval; DS 5 depressive symptoms; DSM-
IV 5 Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition); EODS 5 early-onset depressive symptoms;
GM 5 gray matter; HR 5 hazard ratio; LODS 5 late-onset depressive symptoms; MMSE 5 Mini-Mental State Examination;
MPRAGE 5 magnetization-prepared rapid-acquisition gradient echo; RUN DMC 5 Radboud University Nijmegen Diffusion
Tensor and Magnetic Resonance Cohort; SAT 5 speed–accuracy trade-off; SVD 5 small vessel disease; TBV 5 total brain
volume; WM 5 white matter; WMH 5 white matter hyperintensity.
Depressive symptoms (DS) occur in approximately 30% of patients with dementia1 and have
been coined a risk factor for,2 an early symptom of,3 or a reaction to perceived cognitive decline.
Both cross-sectional and longitudinal population-based studies have investigated this, showing
conflicting results.4–8
Late-onset DS (LODS), initially occurring in older age, should be distinguished from early-
onset DS (EODS), for a different etiology is presumed.9,10 Particularly LODS, rather than
EODS, were found to be related to incident dementia.11 It is unclear whether LODS increase
dementia risk alone or whether this is mediated by the same underlying cerebral small vessel
disease (SVD).9,12–14 SVD refers to neuroradiologic findings, including white matter hyper-
intensities (WMH), lacunes of presumed vascular origin (lacunes), and microbleeds.15
One recent study in older adults with SVD has already shown that DS were associated with
an increased risk of cognitive decline after 3 years, independent of WMH.16 However,
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important adjustments for other aspects of the
SVD spectrum as well as gray matter (GM)
and hippocampal volume were not made.
Therefore, we prospectively investigated the
role of baseline DS on the risk of all-cause
dementia in adults with SVD, also considering
SVD characteristics and other well-known
confounders. Second, we investigated the risk
of dementia, stratified by age at onset of DS,
as LODS and EODS might have different
relations with incident dementia. Finally, we
investigated the relation between DS and inci-
dent dementia in those with high and low cog-
nitive performance at baseline.
METHODS Study population. The Radboud University
Nijmegen Diffusion Tensor and Magnetic Resonance Cohort
(RUNDMC study) is a prospective cohort study investigating risk fac-
tors and clinical consequences of brain changes during aging as assessed
with MRI among 503 older adults without dementia aged 50 to 85
years with cerebral SVD. The recruitment, study rationale, and proto-
col were described previously in detail.17 SVD was defined on estab-
lished research criteria (presence of any WMH and/or lacunes of
presumed vascular origin),18 as SVD onset is often insidious and clin-
ically heterogeneous with acute (TIAs or lacunar syndromes) or sub-
acute (cognitive, motor, and/or mood disturbances) symptoms.
Baseline data collection was performed in 2006.Main exclusion criteria
were dementia, WMH, or SVD mimics, current (psychiatric) disease
interfering with cognitive testing (such as current major depression) or
follow-up, history of serious mental illness, andMRI contraindications
(e.g., pacemaker, vascular clips, and known claustrophobia).17
Follow-up occurred in 2011–2012. Of 503 baseline partic-
ipants, 2 were lost to follow-up (not deceased; figure e-1 at
Neurology.org); 5 additional participants were excluded because
of missing values on the Center for Epidemiologic Studies
Depression Scale (CES-D), yielding a final sample of 496.
Standard protocol approvals, registrations, and patient
consents. This study was approved by the Medical Review
Ethics Committee region Arnhem-Nijmegen. All participants
gave written informed consent before inclusion.
Assessment of DS. DS were assessed with the 20-item CES-D.19
DS were considered present when participants had a CES-D score
$16 and/or currently used antidepressants, taken for depression.
Sixty-one participants used antidepressive medication.20
Furthermore, participants were interviewed about their his-
tory of depressive episodes, onset age, and whether they asked
for medical advice. If depressive episodes had required attention
of a general practitioner, psychologist, or psychiatrist, a history
of depression was considered present.21 To distinguish between
LODS and EODS, we used the age of 60 as the cutoff point.21
Those with a CES-D score $16 and/or current use of antide-
pressants, age 60 years or older, without a history of depressive
episodes before the age of 60, were classified as having LODS.
Those with a CES-D score ,16, without a history of DS and
without current use of antidepressants, formed the reference
group. The others (first depressive episode when younger than
60 years) fulfilled the criteria for EODS (table e-1).22
Dementia case finding. At baseline, all participants were free of
dementia. Dementia case finding and assessment of time to
dementia were described in detail previously.23,24 In short,
dementia case finding was performed for all 501 participants:
those who participated in the in-person follow-up and among
those who could not (died or refused) (figure e-1). Participants
who screened positive at in-person follow-up (MMSE score #26
or a decline $3 points from baseline) were subsequently
examined for dementia at the Radboud Alzheimer Center. For
those who refused this examination, the panel, consisting of
members of the same Radboud Alzheimer Center (to ensure
a standardized approach), came to a consensus diagnosis. This
panel reviewed all available neuropsychological17,23 and imaging
information next to interference in daily functioning, confirmed
by family or caregivers.
For those who were not available for an in-person assessment,
the same panel reviewed the medical records. Furthermore, we
contacted patients’ general practitioners and medical specialists
for information on cognitive status. The dementia diagnosis was
based on DSM-IV criteria.25 Incident dementia was diagnosed in
43 cases. Data on baseline DS were not available for 2 patients
who developed dementia; therefore, 41 cases of incident dementia
are included in the analysis (figure e-1).
MRI protocol and analyses. MRI scans were performed on
a single 1.5-tesla MRI, on average 19 days after assessment at our
research center. The protocol included, among other sequences,
a T1-weighted 3-dimensional magnetization-prepared rapid-
acquisition gradient echo (MPRAGE) imaging (voxel size 1.0 3
1.0 3 1.0 mm); fluid-attenuated inversion recovery (voxel size
1.0 3 1.2 3 5.0 mm, with an interslice gap of 1 mm); and
a transversal T2*-weighted gradient echo sequence (voxel size
1.3 3 1.0 3 6.0 mm, with an interslice gap of 1 mm).17
WMH were manually segmented on fluid-attenuated inver-
sion recovery images. Total WMH volume was calculated by
summing the segmented areas multiplied by slice thickness. La-
cunes and microbleeds were assessed by raters blinded to all clin-
ical data, according to the Standards for Reporting Vascular
Changes on Neuroimaging criteria,15 with good intra- and inter-
rater variability.23 To obtain GM (cortex, basal ganglia, and thal-
amus), white matter (WM), and CSF volume, the T1 MPRAGE
images were segmented using Statistical Parametric Mapping 12
unified segmentation routines (Wellcome Department of Cogni-
tive Neurology, University College London, UK http://www.fil.
ion.ucl.ac.uk/spm/software/spm12/).23 To obtain GM,WM, and
CSF volumes, all voxel volumes that had a p . 0.5 for belonging
to that tissue class were summed. Intracranial volume was a sum-
mation of total GM, total WM, and CSF volume. Total brain
volume (TBV) was a summation of GM and WM volume. We
visually checked all images for coregistration errors and for
motion and/or segmentation artifacts. Hippocampal volumes
were manually segmented on the MPRAGE image using the
interactive software program ITK-SNAP, as described previ-
ously26,27 (http://www.itksnap.org). To adjust for head size, all
volumes were normalized to the intracranial volume.
Other measurements. Education was classified using 7 catego-
ries (1 represented less than primary school, 7 an academic
degree).28 We then dichotomized in primary or less (levels 1–2)
or more than primary education (levels 3–7). Speed–accuracy
trade-off (SAT) scores were calculated where appropriate
(accuracy [%]/reaction time) to adjust for a number of faults.
The Cognitive Index was constructed to obtain a more robust
outcome measure for global cognition. In short, this was
calculated as the mean of the z scores of the SAT score of the
Paper and Pencil Memory Scanning Task, the mean of the SAT
score of the reading task of the Stroop test, the mean of the
Symbol-Digit Substitution Task, and the mean of the added
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score on the 3 learning trials of the Rey Auditory Verbal Learning
Test, and the mean of the Delayed Recall of this test.29 Functional
independence was assessed using the Barthel Index (range, 0–
20).17 All other measurements were done at initial assessment.
Statistical analyses. WMH volume was log-transformed
because of the skewness of the data. Cumulative risk of
incident dementia was estimated with Kaplan-Meier analysis
stratified by presence of baseline DS. Person-years at risk were
calculated for each participant from date of the baseline
assessment, until onset of dementia, death, or date of the
follow-up assessment. Those who did not reach the endpoint or
died were censored. Subsequently, we used incidence curves to
compare between subgroups using log-rank test. We used Cox
regression analyses to calculate hazard ratios (HRs) with 95%
confidence intervals (CIs) for presence of baseline DS (total,
EODS, and LODS), adjusted for age, sex, and education
(model 1), additional for baseline Cognitive Index and TBV
(model 2), additional for WMH volume, presence of lacunes
and microbleeds (model 3), or additional for GM and
hippocampal volume (model 4). Verification of proportionality
of hazards was performed by examining Schoenfeld residuals;
there were no indications that this assumption was violated.
Finally, to identify the role of DS on the dementia risk in
“high cognitive performers” and “low cognitive performers” at
baseline (defined by compound z score Cognitive Index below
the median at baseline; table e-2), we performed Kaplan-Meier
analyses and compared subgroups with log-rank test.
RESULTS Baseline demographic and neuroimaging
characteristics (n 5 496) are shown in tables 1 and
e-3, respectively. At baseline, 33.7% of participants
had DS. Dementia developed in 41 of the 496
participants during a mean follow-up of 5.2 years
(SD 0.7). Mean age at baseline was 65.6 years (SD
8.8), and 56.9% were men. Mean MMSE score at
baseline was 28.1 (SD 1.6). The 5.5-year cumulative
risk of dementia was higher in participants with DS at
baseline compared with those without (DS 18.5% vs
no DS 7.4%, log-rank p 5 0.003) (figure 1).
Baseline DS significantly predicted incident
dementia after 5 years of follow-up, adjusted for
age, sex, and education (HR 2.7, 95% CI 1.4–5.2).
Additional adjustment for baseline Cognitive Index
and TBV, SVD characteristics (WMH volume, la-
cunes, and microbleeds), or GM structures (hippo-
campal and GM volume) did not significantly alter
these findings (data not shown). The unadjusted
cumulative risk of incident dementia in those with
EODS and LODS separately compared to those who
never experienced DS is presented in figure 2. LODS
predicted incident dementia (HR 2.5, 95% CI 1.3–
4.8); adjustments for the above-mentioned con-
founders did not change this relation substantially
(data not shown). For EODS, this relation with inci-
dent dementia was not found (table 2).
Finally, figure 3 shows the cumulative risk of
dementia in strata of baseline cognitive performance
for participants with and without DS. In depressed
participants with high baseline cognitive perfor-
mance, there was a significant 5-year cumulative risk
difference for dementia (no DS 0.0% vs DS 6.9%,
Table 1 Baseline characteristics of participants with and without depressive symptoms at baseline assessment
Characteristic Total (N 5 496)
Depressive symptoms at
baseline (n 5 167)
No depressive symptoms at
baseline (n 5 329)
p Value for
differencea
Age at baseline (SD), y 65.6 (8.8) 65.9 (8.7) 65.4 (8.8) 0.607b
Men, n (%) 282 (56.9) 81 (48.5) 201 (61.1) 0.007c
Only primary education, n (%) 48 (9.7) 26 (15.6) 22 (6.7) 0.002c
CES-D score at baseline (SD) 11.0 (9.4) 21.1 (8.5) 5.9 (4.4) 0.001d
Antidepressive medication use at baseline, n (%) 61 (12.3) 61 (36.5) 0 (0.0) NA
History of depression, n (%) 127 (25.6) 85 (50.9) 42 (12.8) 0.001c
MMSE baseline score (SD) 28.1 (1.6) 27.7 (1.7) 28.3 (1.6) ,0.001d
Compound z score Cognitive Index (SD)e 20.0 (0.8) 20.3 (0.7) 0.1 (0.8) ,0.001b
Low cognitive performance, n (%)e 247 (49.8) 107 (64.1) 140 (42.6) ,0.001c
Dementia at follow-up, n (%) 41 (8.3) 22 (13.2) 19 (5.8) 0.005c
Barthel Index (SD) 19.7 (0.8) 19.5 (1.1) 19.8 (0.6) 0.011b
Abbreviations: CES-D 5 Center for Epidemiologic Studies Depression Scale; MMSE 5 Mini-Mental State Examination.
Data shown are unadjusted values and represent n (%) and mean (SD). Of the 503 participants at baseline, 2 were lost to follow-up. Five additional
participants were excluded because of missing values on the status of depression at baseline (one was excluded because of missing cognitive tests at
baseline). The Cognitive Index is a compound z score of the paper and pencil test, Stroop test, Symbol-Digit Substitution Task, and immediate and delayed
recall of the 15-word list of the Rey Auditory Verbal Learning Test. Low cognitive performance is defined by a compound z score of the Cognitive Index
below the median at baseline.
aComparison of those with and without depressive symptoms at baseline.
bMeans compared with independent t test.
c Chi-square test.
dMann–Whitney U.
e One participant was excluded because of missing cognitive tests at baseline.
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log-rank p , 0.001), whereas no such difference was
found between participants with and without DS
with low cognitive performance (no DS 9.7% vs
DS 12.2%, log-rank p 5 0.514). Adjustment for
demographic and imaging confounders in Cox regres-
sion analyses in both good and poor cognitive perfor-
mance did not change this relation. Low dementia
risk in participants without DS with good cognitive
performance led to wide CIs (HR 40.2, 95% CI 4.5–
361.8).
The interaction between DS and cognitive perfor-
mance on dementia risk showed a significant effect
(HR 25.3, 95% CI 2.6–238.7; p 5 0.005). We did
not find a significant interaction between sex or low
education and DS (data not shown).
DISCUSSION Our results show that DS increase the
dementia risk after 5 years in older adults with SVD,
a relation that is driven by those who develop a first
depressive episode at later age. This relation is inde-
pendent of SVD characteristics and GM and hippo-
campal volumes, suggesting additional factors
besides SVD have a role in our cohort in development
of dementia. We showed that DS are related to an
increased risk of dementia in those without objective
cognitive problems. The magnitude of this relation,
however, cannot be estimated because of the small
number of incident cases in this subgroup. Below,
we discuss the significance of these findings in more
detail.
Strengths of our study include its longitudinal and
single-center design allowing us to collect both base-
line and follow-up data according to identical proce-
dures, reducing the risk of procedural bias.
Subsequently, the large cohort that covers the whole
spectrum of cerebral SVD and the high follow-up rate
Figure 1 Cumulative risk of dementia stratified by presence of depressive
symptoms at baseline
Unadjusted percentages. Log-rank test pairwise over strata.
Figure 2 Cumulative risk of dementia stratified by onset of depressive symptoms
Unadjusted percentages. Log-rank test pairwise over strata. EODS5 early-onset depressive symptoms; LODS5 late-onset
depressive symptoms.
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of 99.6% are major strengths. We manually seg-
mented WMH and hippocampal volumes without
prior knowledge of clinical data. Finally, the relation
between DS and incident dementia was investigated
with adjustment for demographics, baseline global cog-
nition, SVD, and GM structures, reducing confounds.
Several methodological issues need to be ad-
dressed. First, we investigated “overall dementia” as
an outcome measure and did not investigate the risk
of Alzheimer disease and vascular dementia sepa-
rately. This distinction is difficult to make in elderly
persons since at a later age vascular diseases and neu-
rodegeneration often co-occur.30 Our dementia diag-
nosis was a clinical diagnosis, supported by MRI most
closely performed to the moment of diagnosis. It is
possible that we have missed a few cases of incident
dementia in participants who were not available for
in-person follow-up, because of incomplete medical
records or uninformed general practitioners. In those
cases, misclassification could have occurred in rela-
tively early stages of dementia. Second, although
widely used, the cutoff point of 26 in the MMSE
might not be sensitive enough to detect all incident
dementia cases, especially for those in an early stage of
the disease, those with vascular dementia, or in par-
ticipants with dementia who have higher education
levels. Therefore, misclassification, which might have
led to an underestimation of the effect, might have
occurred. Third, the relation between DS and inci-
dent all-cause dementia was adjusted for demographic
and imaging characteristics and for baseline cognitive
performance, reducing confounders. However, the
small number of dementia cases in some of the sub-
groups resulted in wide confidence intervals, prevent-
ing a reliable estimate of the magnitude of the effect.
Therefore, these results should be interpreted with
Table 2 Cox proportional hazards for dementia by baseline depression status,
early-onset depressive symptoms, and late-onset depressive
symptoms
Progression to
dementia, n (%)
HR (95% CI),
adjusted for age,
sex, and education
Depressive symptoms
No depressive symptoms (n 5 329) 19 (5.8) 1
Depressive symptoms (n 5 167) 22 (13.2) 2.7 (1.4–5.2)a
Early-onset (<60 y)
No depressive symptoms (n 5 287) 19 (6.6) 1
Early-onset depressive symptoms (n 5 107) 1 (0.9) 0.2 (0.02–1.7)
Late-onset (‡ 60 y)
No depressive symptoms (n 5 287) 19 (6.6) 1
Late-onset depressive symptoms (n 5 101) 21 (20.6) 2.5 (1.3–4.8)a
Abbreviations: CI 5 confidence interval; HR 5 hazard ratio.
Of the 503 participants at baseline, 2 were lost to follow-up. Five additional participants were
excluded because of missing values on the status of depression at baseline resulting in a total of
496 participants. Late-onset depressive symptoms: patients aged 60 years or older with a Center
for Epidemiologic Studies Depression Scale (CES-D) score$16 and/or current use of antidepres-
sive medication, taken for depression, without a history of depressive episodes when younger
than 60 years. Early-onset depressive symptoms: a CES-D score $16 and/or current use of
antidepressive medication, taken for depression, and/or a history of depressive episodes when
younger than 60 years. Individuals with a CES-D score ,16, without a history of depressive
symptoms and without current use of antidepressive medication, formed the reference group.
Verification of proportionality of hazards was performed by examining Schoenfeld residuals.
a Significant.
Figure 3 Cumulative risk of dementia stratified by presence of depressive symptoms in participants with high and low cognitive performance
at baseline
Cumulative risk of dementia in participants with high (A) and low (B) cognitive performance at baseline. Unadjusted percentages. Log-rank test pairwise over
strata. High cognitive performance defined as the upper-half Cognitive Index at baseline; low cognitive performance defined as the lower-half Cognitive
Index at baseline.
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caution. Furthermore, our analyses were not adjusted
for other relevant confounders such as lifestyle risk
factors and functional health, which might have led to
residual confounding. Finally, we used the CES-D
and/or current use of antidepressive medication to
assess DS. Although used in large population-based
studies,4,31 it is also considered a screen for general
affective distress, and therefore not a specific screen-
ing tool for DS. To account for this, we excluded
participants at baseline with serious mental illness.
We think that our study has an excellent external
validity regarding vulnerability for cognitive and
affective symptoms in patients between 50 and 85
years of age presenting with SVD on neuroimaging
in a neuropsychiatric clinic. All of our participants
were functionally independent at baseline, with
a mean MMSE score of 28.1 (SD 1.6), reflecting es-
timates in the general population. The incidence rate
for dementia in our SVD cohort is higher than in
a large population-based study.32 This is not surpris-
ing as SVD is associated with incident dementia.12
When we compared our incidence rate of dementia
with another SVD cohort,16 our incidence rate was
actually lower. This could be explained by the
approximately 10 years younger mean age of our
population and also the less severe WMH at baseline;
both factors are known to be related to the incidence
of dementia.32,33
Our findings that DS are associated with all-cause
dementia are accounted for by those participants with
LODS. At the same time, we showed that EODS
were not related to incident dementia in older adults
with SVD. This is an important finding because (lon-
ger existing) EODS would be expected to increase
dementia risk, for they have shown to be associated
with neurodegeneration through neurotoxic mecha-
nisms, including hippocampus atrophy.34,35 This
could suggest that LODS present not a causal factor
for incident dementia, but rather are an early symp-
tom of the spectrum, ultimately leading to dementia,
for they present relatively shortly before dementia
onset.
There are several hypothesized explanations for
(late-onset) DS as an early symptom of dementia.36
Disruption of the subcortical-frontal circuit, for
example, by SVD or neurodegenerative processes
could result in both LODS and cognitive difficulties,
such as dysexecutive problems and slower speed of
information processing.20,37–39 This structural defect
might also explain resistance to treatment, which is
common in late-life depression. Of note, in our study
we found that the association between DS and inci-
dent dementia remained present after adjustment for
SVD characteristics, suggesting that additional factors
besides SVD have a role that may not be necessarily
depicted at the macroanatomical level. This is in line
with other longitudinal studies on depression and
dementia.16,40
We showed in an SVD population that partici-
pants with DS have a higher risk of incident dementia
compared to those without DS while performing rel-
atively well cognitively. This finding could not be
merely explained by the level of education, as post
hoc analyses showed that all of those with incident
dementia in the group that performed relatively well
cognitively had more than primary education (data
not shown). While it seems somewhat counterintui-
tive at first glance, it may very well be that only in
those with relatively high cognitive performance,
DS are indicative of incident dementia. Because cog-
nitive performance at baseline is a very strong risk fac-
tor for incident dementia, it is possible that in the
group with relatively low cognitive performance, pres-
ence of DS adds no significant value to the overall
dementia risk. This is another argument suggesting
that both (cognitive and affective) symptoms are part
of the same underlying pathophysiology, whereby DS
may present an early symptom rather than a risk fac-
tor for dementia.
The information presented above could imply that
the presence of DS might be a sensitive tool to inves-
tigate future dementia risk, possibly more sensitive
than cognitive evaluation, in those with a relatively
higher cognitive status. In contrast to current clinical
practice, these patients in particular should be ade-
quately monitored for occurrence of cognitive decline,
while those without DS have a very low 5-year risk of
developing dementia. This is important to acknowl-
edge, beginning with the general practitioner, who
must recognize these first DS at older age as an initial
sign of dementia. After this, the diagnostic path calls
for a multidisciplinary approach in which there must
be good cooperation among psychiatrists, clinical neu-
ropsychologists, and neurologists.
Our results show that LODS increase the risk of
all-cause dementia in elderly persons with SVD, but
independent thereof, suggesting that other factors
also have a role. It is possible that DS in older age
are an early symptom rather than an independent risk
factor for incident dementia. General practitioners
and medical specialists should be alert to the presence
of DS and also monitor those with relatively good
cognitive test scores while presenting with DS.
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